Nuzenio

Bispecific Antibody Therapy

Bispecific Antibody Therapy news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 17 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 04:31:46 GMTOutpatient Bispecific Antibodies: Considerations for Step-Up Dosing, CRS, and ICANS - OncodailyOncodaily · Sat, 08 Aug 2026 09:01:53 GMTWhy CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma - CancerNetworkCancerNetwork · Fri, 07 Aug 2026 15:09:51 GMTThe Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials? - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 19:09:04 GMTAdverse Event Management for Bispecific Antibodies and CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 12:42:09 GMTREMS Programs for BCMA-Directed Therapies: Background, Best Practices, and Institutional Protocols - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 12:42:09 GMTContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 09:55:15 GMTTargeted myeloma treatment shows promise in Phase 1 trial - Rare Cancer NewsRare Cancer News · Thu, 06 Aug 2026 07:00:00 GMT

Timeline

Mon, 10 Aug 2026 04:31:46 GMTAkeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila Times
Sat, 08 Aug 2026 09:01:53 GMTOutpatient Bispecific Antibodies: Considerations for Step-Up Dosing, CRS, and ICANS - Oncodaily
Fri, 07 Aug 2026 15:09:51 GMTWhy CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma - CancerNetwork
Thu, 06 Aug 2026 19:09:04 GMTThe Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials? - CancerNetwork
Thu, 06 Aug 2026 12:42:09 GMTAdverse Event Management for Bispecific Antibodies and CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma - Pharmacy Times
Thu, 06 Aug 2026 12:42:09 GMTREMS Programs for BCMA-Directed Therapies: Background, Best Practices, and Institutional Protocols - Pharmacy Times

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.CricketCricket stories move through fixtures, squads, match situations, injuries, tournaments, league business, and fan reaction.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Bispecific Antibody Therapy.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.